Search - tctmd.com

Displaying 301 - 309 of 309

Sort: Relevancy | Date

News Conference News ACC 2012

Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism

L.A. McKeown

March 26, 2012

News Daily News ISET 2012

Jugular Angioplasty for MS May Improve Perceived Quality of Life

L.A. McKeown

March 21, 2012

News Daily News

Early Percutaneous Intervention May Help Asymptomatic Mitral Stenosis

Caitlin E. Cox

January 17, 2012

News Daily News

Catheter-Directed Thrombolysis Beneficial for Proximal DVT

Yael L. Maxwell

December 12, 2011

News Industry News

FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation

September 08, 2011

News Daily News

Carbon Dioxide Angiography May Be Alternative to Iodinated Contrast in High-Risk Patients

L.A. McKeown

August 16, 2011

News Daily News

Early Morning Circadian Rhythms Linked to Stent Thrombosis

February 21, 2011

News Industry News

EKOS Corporation Receives CE Mark to Treat Massive and Sub-Massive Pulmonary Embolism

January 16, 2011

News Industry News

Bayer’s Rivaroxaban Submitted for EU Marketing Authorisation in Stroke Prevention in Patients with Atrial Fibrillation as well as for the Treatment of Deep Vein Thrombosis

January 04, 2011

Advertisement

Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism

Jugular Angioplasty for MS May Improve Perceived Quality of Life

Early Percutaneous Intervention May Help Asymptomatic Mitral Stenosis

Catheter-Directed Thrombolysis Beneficial for Proximal DVT

FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation

Carbon Dioxide Angiography May Be Alternative to Iodinated Contrast in High-Risk Patients

Early Morning Circadian Rhythms Linked to Stent Thrombosis

EKOS Corporation Receives CE Mark to Treat Massive and Sub-Massive Pulmonary Embolism

Bayer’s Rivaroxaban Submitted for EU Marketing Authorisation in Stroke Prevention in Patients with Atrial Fibrillation as well as for the Treatment of Deep Vein Thrombosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content